These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 35873012)

  • 1. Expression Modulation of Immune Checkpoint Molecules by Ibrutinib and Everolimus Through STAT3 in MCF-7 Breast Cancer Cells.
    Soltanshahi M; Taghiloo S; Asgarian-Omran H
    Iran J Pharm Res; 2022 Dec; 21(1):e127352. PubMed ID: 35873012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effects of PI3K/Akt/mTOR Signaling Pathway Inhibitors on the Expression of Immune Checkpoint Ligands in Acute Myeloid Leukemia Cell Line.
    Taghiloo S; Norozi S; Asgarian-Omran H
    Iran J Allergy Asthma Immunol; 2022 Apr; 21(2):178-188. PubMed ID: 35490271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma.
    Li J; Wang X; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Pan Z; Ding N; Song Y; Zhu J
    Int J Cancer; 2018 Jan; 142(1):202-213. PubMed ID: 28905990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway.
    Kondo K; Shaim H; Thompson PA; Burger JA; Keating M; Estrov Z; Harris D; Kim E; Ferrajoli A; Daher M; Basar R; Muftuoglu M; Imahashi N; Alsuliman A; Sobieski C; Gokdemir E; Wierda W; Jain N; Liu E; Shpall EJ; Rezvani K
    Leukemia; 2018 Apr; 32(4):960-970. PubMed ID: 28972595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fructose-1,6-bisphosphatase loss modulates STAT3-dependent expression of PD-L1 and cancer immunity.
    Wang B; Zhou Y; Zhang J; Jin X; Wu H; Huang H
    Theranostics; 2020; 10(3):1033-1045. PubMed ID: 31938049
    [No Abstract]   [Full Text] [Related]  

  • 6. B-cell receptor-mediated NFATc1 activation induces IL-10/STAT3/PD-L1 signaling in diffuse large B-cell lymphoma.
    Li L; Zhang J; Chen J; Xu-Monette ZY; Miao Y; Xiao M; Young KH; Wang S; Medeiros LJ; Wang M; Ford RJ; Pham LV
    Blood; 2018 Oct; 132(17):1805-1817. PubMed ID: 30209121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The mechanism of low-dose radiation-induced upregulation of immune checkpoint molecule expression in lung cancer cells.
    Wan X; Fang M; Chen T; Wang H; Zhou Q; Wei Y; Zheng L; Zhou Y; Chen K
    Biochem Biophys Res Commun; 2022 Jun; 608():102-107. PubMed ID: 35397421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of galectin-3 augments the antitumor efficacy of PD-L1 blockade in non-small-cell lung cancer.
    Zhang H; Liu P; Zhang Y; Han L; Hu Z; Cai Z; Cai J
    FEBS Open Bio; 2021 Mar; 11(3):911-920. PubMed ID: 33455075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ibrutinib Inhibits BTK Signaling in Tumor-Infiltrated B Cells and Amplifies Antitumor Immunity by PD-1 Checkpoint Blockade for Metastatic Prostate Cancer.
    Deng G; He J; Huang Q; Li T; Huang Z; Gao S; Xu J; Wang T; Di J
    Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment.
    Stiff A; Trikha P; Wesolowski R; Kendra K; Hsu V; Uppati S; McMichael E; Duggan M; Campbell A; Keller K; Landi I; Zhong Y; Dubovsky J; Howard JH; Yu L; Harrington B; Old M; Reiff S; Mace T; Tridandapani S; Muthusamy N; Caligiuri MA; Byrd JC; Carson WE
    Cancer Res; 2016 Apr; 76(8):2125-36. PubMed ID: 26880800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment by PI3K/mTOR Inhibitor BEZ235 Combined with TLR-7/8 Agonist Interfere with Immune Evasion Mechanisms of WEHI-3 Mouse Leukemia Cells.
    Taghiloo S; Ajami A; Alizadeh-Navaei R; Zaboli E; Asgarian-Omran H
    Iran J Immunol; 2022 Mar; 19(1):6. PubMed ID: 35293347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Shikonin-mediated PD-L1 degradation suppresses immune evasion in pancreatic cancer by inhibiting NF-κB/STAT3 and NF-κB/CSN5 signaling pathways.
    Ruan Z; Liang M; Shang L; Lai M; Deng X; Su X
    Pancreatology; 2021 Apr; 21(3):630-641. PubMed ID: 33707115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Everolimus (RAD001) combined with programmed death-1 (PD-1) blockade enhances radiosensitivity of cervical cancer and programmed death-ligand 1 (PD-L1) expression by blocking the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR)/S6 kinase 1 (S6K1) pathway.
    Song L; Liu S; Zhao S
    Bioengineered; 2022 Apr; 13(4):11240-11257. PubMed ID: 35485300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The combination therapy of Everolimus and anti-PD-1 improves the antitumor effect by regulating CD8
    Xia W; Zhang S; Duan H; Wang C; Qian S; Shen H
    Med Oncol; 2022 Jan; 39(3):37. PubMed ID: 35059863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.
    Wang X; Wong J; Sevinsky CJ; Kokabee L; Khan F; Sun Y; Conklin DS
    Mol Cancer Ther; 2016 Sep; 15(9):2198-208. PubMed ID: 27256378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
    Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
    Front Immunol; 2021; 12():766272. PubMed ID: 34912339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of CD155 is associated with PD-1 and PD-L1 expression on immune cells, rather than tumor cells in the breast cancer microenvironment.
    Wang RB; Li YC; Zhou Q; Lv SZ; Yuan KY; Wu JP; Zhao YJ; Song QK; Zhu B
    World J Clin Cases; 2020 Dec; 8(23):5935-5943. PubMed ID: 33344592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Curcumol inhibits the expression of programmed cell death-ligand 1 through crosstalk between hypoxia-inducible factor-1α and STAT3 (T705) signaling pathways in hepatic cancer.
    Zuo HX; Jin Y; Wang Z; Li MY; Zhang ZH; Wang JY; Xing Y; Ri MH; Jin CH; Xu GH; Piao LX; Ma J; Jin X
    J Ethnopharmacol; 2020 Jul; 257():112835. PubMed ID: 32278762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The immune suppressive factors CD155 and PD-L1 show contrasting expression patterns and immune correlates in ovarian and other cancers.
    Smazynski J; Hamilton PT; Thornton S; Milne K; Wouters MCA; Webb JR; Nelson BH
    Gynecol Oncol; 2020 Jul; 158(1):167-177. PubMed ID: 32446718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bruton's tyrosine kinase (BTK) as a promising target in solid tumors.
    Molina-Cerrillo J; Alonso-Gordoa T; Gajate P; Grande E
    Cancer Treat Rev; 2017 Jul; 58():41-50. PubMed ID: 28641100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.